MGI Purchase Of Guilford Will Create Two-Product Acute Care Sales Force
This article was originally published in Pharmaceutical Approvals Monthly
MGI Pharma's acquisition of Guilford will forge a two-product acute care sales force
You may also be interested in...
MGI and SuperGen estimate their myelodysplastic syndrome agent Dacogen has a market potential of $250 mil., SuperGen said July 21.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011